title: Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
abstract: CD8(+)CD62L(+) T cells have been shown to play pivotal roles in anti-viral immunity, chronic myeloid leukemia and renal cell carcinoma. Recently, CD8(+)CD62L(+) T cells from naïve mice (nCD8(+)CD62L(+) T cells) have shown superior anti-tumor properties in melanoma-bearing mice. Considering that antigen-specific memory T cells have shown to possess more potent immunity than non-specific memory T cells, we hypothesized that CD8(+)CD62L(+) T cells from tumor-bearing individuals (mCD8(+)CD62L(+) T cells) might have superior anti-tumor effect than nCD8(+)CD62L(+) T cells. Therefore, we investigated phenotypes, functions and the in vivo distribution of mCD8(+)CD62L(+) T cells in tumor-bearing mice. We found that, while keeping the features of central memory T cells, the frequency of mCD8(+)CD62L(+) T cell in the spleen of tumor-bearing mice was significantly higher than that the one of nCD8(+)CD62L(+) T cell in naive mice. Moreover, we demonstrated that mCD8(+)CD62L(+) T cells had higher proliferation rate and IFN-γ production than nCD8(+)CD62L(+) T cells, in vitro. We performed adoptive transfer of mCD8(+)CD62L(+) T cells into melanoma-bearing mice and tracked them in spleen, lymph nodes and in melanoma tissues. Our results show that mCD8(+)CD62L(+) T cells had stronger in vivo anti-tumoral activity than nCD8(+)CD62L(+) T cells. This study highlights the therapeutic potential of mCD8(+)CD62L(+) T cells in the immunotherapy of melanoma and possibly other tumors.
authors.affiliation: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University , Chongqing , China , and.
authors.forename: Yunmei
authors.initials: Y
authors.lastname: Liao
authors.forename: Peiliang
authors.initials: P
authors.lastname: Geng
authors.forename: Yi
authors.initials: Y
authors.lastname: Tian
authors.forename: Hongning
authors.initials: H
authors.lastname: Miao
authors.forename: Houjie
authors.initials: H
authors.lastname: Liang
authors.forename: Rui
authors.initials: R
authors.lastname: Zeng
authors.forename: Bing
authors.initials: B
authors.lastname: Ni
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Ruan
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000378:metabolism; D017209:Apoptosis / Q000276:immunology; D015415:Biomarkers; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000096:biosynthesis; D019041:L-Selectin / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000276:immunology; D018655:Lymphocyte Count; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000378:metabolism; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D051379:Mice; D010641:Phenotype; D013154:Spleen / Q000166:cytology / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism
chemical_list: D000954:Antigens, Surface; D015415:Biomarkers; D019041:L-Selectin; D007371:Interferon-gamma
keywords: Anti-tumor immunity; CD8+CD62L+ T cells; T subtypes; melanoma